

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* GIVEN BRUCE D _____ (Last) (First) (Middle) 177 E. COLORADO BLVD SUITE 700 _____ (Street) PASADENA CA 91105 _____ (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol ARROWHEAD PHARMACEUTICALS, INC. [ARWR]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ Chief Operating Officer	
			3. Date of Earliest Transaction (Month/Day/Year) 04/20/2020			
			4. If Amendment, Date of Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/20/2020		M		3,800	A	\$4.75	862,793	D	
Common Stock	04/20/2020		M		3,700	A	\$5.19	866,493	D	
Common Stock	04/20/2020		M		3,456	A	\$5.2	869,949	D	
Common Stock	04/20/2020		M		5,300	A	\$14.54	875,249	D	
Common Stock	04/20/2020		s ⁽¹⁾		3,800	D	\$40 ⁽²⁾	871,449	D	
Common Stock	04/20/2020		s ⁽¹⁾		3,700	D	\$40 ⁽³⁾	867,749	D	
Common Stock	04/20/2020		s ⁽¹⁾		3,456	D	\$40 ⁽²⁾	864,293	D	
Common Stock	04/20/2020		s ⁽¹⁾		5,300	D	\$40 ⁽³⁾	858,993	D	
Common Stock	04/20/2020		s ⁽¹⁾		3,454	D	\$40 ⁽²⁾	855,539	D	
Common Stock	04/20/2020		s ⁽¹⁾		3,805	D	\$40 ⁽²⁾	851,734	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (right to buy)	\$4.75	04/20/2020		M		3,800		10/01/2013 ⁽⁴⁾	09/21/2023	Common Stock	3,800	\$0.00	346,200	D	
Stock Option (right to buy)	\$5.19	04/20/2020		M		3,700		03/01/2012 ⁽⁴⁾	02/16/2022	Common Stock	3,700	\$0.00	342,500	D	
Stock Option (right to buy)	\$5.2	04/20/2020		M		3,456		04/01/2012 ⁽⁴⁾	10/26/2021	Common Stock	3,456	\$0.00	339,044	D	
Stock Option (right to buy)	\$14.54	04/20/2020		M		5,300		03/01/2014 ⁽⁴⁾	02/06/2024	Common Stock	5,300	\$0.00	333,744	D	

Explanation of Responses:

- Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$40.00 to \$40.01, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$40.00 to \$40.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- Represents first vesting date. Option vested over four years from date of grant.

Remarks:

/S/ Bruce Given

04/22/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.